Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
9.17
-0.15 (-1.61%)
At close: Jul 24, 2026, 4:00 PM EDT
9.18
+0.01 (0.11%)
After-hours: Jul 24, 2026, 7:34 PM EDT
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
36
Market Cap
169.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 881.71K | -3.06M | -77.61% |
| Dec 31, 2020 | 3.94M | -32.21M | -89.11% |
| Dec 31, 2019 | 36.14M | 31.32M | 649.51% |
| Dec 31, 2018 | 4.82M | 2.38M | 97.62% |
| Dec 31, 2017 | 2.44M | 528.77K | 27.66% |
| Dec 31, 2016 | 1.91M | 1.26M | 194.80% |
| Dec 31, 2015 | 648.38K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tonix Pharmaceuticals Holding | 17.56M |
| Pyxis Oncology | 13.86M |
| Innate Pharma | 10.57M |
| Equillium | 4.39M |
| NRx Pharmaceuticals | 2.29M |
| Humacyte | 2.02M |
| Oramed Pharmaceuticals | 2.00M |
CRBP News
- 19 days ago - Corbus Pharmaceuticals appoints Viana Nicacio as chief medical officer - TheFly
- 19 days ago - Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - GlobeNewsWire
- 4 weeks ago - Corbus Pharmaceuticals price target lowered to $34 from $44 at Mizuho - TheFly
- 5 weeks ago - Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer - TheFly
- 7 weeks ago - Corbus Pharmaceuticals Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Corbus Pharmaceuticals Holdings Slides: FY 2026 - Filings
- 7 weeks ago - Corbus Pharmaceuticals Holdings Transcript: KOL event - Transcripts
- 2 months ago - Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush - TheFly